Portal de Periódicos da CAPES

Executive summary of the GeSIDA/National AIDS Plan consensus document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2018)

2018; Elsevier BV; Volume: 37; Issue: 3 Linguagem: Inglês

10.1016/j.eimc.2018.02.010

1695-4114

José A. Pérez‐Molina, Rosa Polo, José López-Aldeguer, Fernando Lozano, Koldo Aguirrebengoa, José Ramón Arribas, Vicente Boix, Juan Berenguer, José Ramón Blanco, Peré Domingo, Vicente Estrada, Marı́a José Galindo, Féderico García, José María Gatell, Juan González‐García, Félix Gutiérrez, José Antonio Iribarren, Hernando Knobel, Josep M. Llibre, Juan Carlos López-Bernaldo de Quirós, Luís F. López‐Cortés, Juan Emilio Losa, Ana Mariño, José M. Miró, Marisa Montes, Santiago Moreno, Eugènia Negredo, Maria Jesús Pérez‐Elías, Daniel Podzamczer, Joaquín Portilla, Eva Poveda, Federico Pulido, Esteban Ribera, Antonio Rivero, Rafael Rubio, Jesús Santos, José Sanz, Jesús Sanz, Sergio E. Serrano, Javier de la Torre, Montserrat Tuset, Miguel Angel Von Wichman, Estebán Martínez,

HIV/AIDS Research and Interventions

This update to the document on antiretroviral therapy (ART) in adults, which has been prepared jointly by GeSIDA and the Spanish National AIDS Plan for the last two decades, supersedes the document published in 2017.1 The update provides physicians treating HIV-1-infected adults with evidence-based recommendations to guide their therapeutic decisions. The main difference with respect to the previous document concerns recommended initial ART regimens, only three of which are maintained as preferential. All three include dolutegravir or raltegravir, together with emtricitabine/tenofovir alafenamide or abacavir/lamivudine. Other differences concern the section on switching ART in patients with suppressed viral replication, which now includes new two- and three-drug regimens, and the antiretroviral drugs recommended for pregnant women and patients with tuberculosis. A recommendation has also been added for patients who present with acute HIV infection after pre-exposure prophylaxis.